- Home
- SPT vs EWTX Comparison
SPT vs EWTX Comparison
Compare SPT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- EWTX
- Stock Information
- Founded
- SPT 2010
- EWTX 2017
- Country
- SPT United States
- EWTX United States
- Employees
- SPT N/A
- EWTX N/A
- Industry
- SPT Computer Software: Prepackaged Software
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- EWTX Health Care
- Exchange
- SPT Nasdaq
- EWTX Nasdaq
- Market Cap
- SPT 1.1B
- EWTX 1.2B
- IPO Year
- SPT 2019
- EWTX 2021
- Fundamental
- Price
- SPT $23.90
- EWTX $14.58
- Analyst Decision
- SPT Buy
- EWTX Buy
- Analyst Count
- SPT 13
- EWTX 8
- Target Price
- SPT $31.69
- EWTX $40.13
- AVG Volume (30 Days)
- SPT 617.7K
- EWTX 1.2M
- Earning Date
- SPT 05-08-2025
- EWTX 05-08-2025
- Dividend Yield
- SPT N/A
- EWTX N/A
- EPS Growth
- SPT N/A
- EWTX N/A
- EPS
- SPT N/A
- EWTX N/A
- Revenue
- SPT $418,413,000.00
- EWTX N/A
- Revenue This Year
- SPT $12.00
- EWTX N/A
- Revenue Next Year
- SPT $12.53
- EWTX N/A
- P/E Ratio
- SPT N/A
- EWTX N/A
- Revenue Growth
- SPT 17.79
- EWTX N/A
- 52 Week Low
- SPT $18.52
- EWTX $10.60
- 52 Week High
- SPT $39.75
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- SPT 64.63
- EWTX 41.67
- Support Level
- SPT $20.34
- EWTX $13.82
- Resistance Level
- SPT $21.84
- EWTX $17.30
- Average True Range (ATR)
- SPT 0.92
- EWTX 1.02
- MACD
- SPT 0.46
- EWTX 0.32
- Stochastic Oscillator
- SPT 86.02
- EWTX 30.43
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.